FABRICATION, CHARACTERIZATION, AND TESTING CORE (FaCT CORE)
制造、表征和测试核心 (FaCT CORE)
基本信息
- 批准号:10557615
- 负责人:
- 金额:$ 57.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-06 至 2028-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcademiaAdvanced DevelopmentAreaAwardBiomedical EngineeringBiomedical ResearchCenters of Research ExcellenceChargeCollaborationsComputersContractsCore FacilityData CollectionDevelopmentDevicesDoctor of PhilosophyEducational workshopEngineeringEquipmentFacultyFaculty RecruitmentGoalsGovernmentGrowthHuman ResourcesIdahoIncentivesIndustryInfrastructureInvestmentsMaintenanceMedical DeviceMicrofabricationOpticsPerformancePersonnel ManagementPlayPrintingPrivatizationProcessResearchResearch PersonnelResearch Project GrantsResearch SupportResearch TrainingResourcesRoleScheduleScienceServicesStructureStudentsSystemTechnologyTestingTrainingUniversitiesValidationWorkapplied biomedical researchbiomedical resourceclinical translationcollegecostdata acquisitionelectrical propertyengineering designfabricationgraduate studentimprovedindustry partnerinnovationinstrumentinstrumentationmaterials sciencemechanical devicemeetingsoperationoutreachprogramsprototypesensorskill acquisitionsymposiumtooltraining opportunityvoucherweb site
项目摘要
PROJECT SUMMARY – FABRICATION, CHARACTERIZATION, AND TESTING CORE (FACT CORE)
The FaCT core will provide the biomedical engineering support needed for RPLs and others to fully engage in
the development, synthesis, and validation of devices, sensors, and systems to be used in foundational or
applied biomedical research and/or clinical-translational work in the COBRE in Convergent Engineering and
Biomolecular Science (CEBS). This innovative engineering-focused core will be a consolidation of four existing
research cores in the College of Engineering, three of which are already recharge centers. The FaCT core will
merge the Idaho Microfabrication Lab IML), the Boise State Center for Materials Characterization (BSCMC),
the Engineering Research Support ERS) center, and the Biomedical Engineering Center (BEC). To meet
CEBS COBRE goals, researchers must be able to fabricate a wide range of devices and structures from
simple mechanical devices to more sophisticated sensors through machining, printing, or microfabrication.
After fabrication, researchers will also need to be able to characterize physical, optical, and electrical
properties of the devices/sensors to assess their performance for the required research. Hence, each research
effort will require use of a variety of tools, instruments, processes, and expertise supplied by FaCT core
facilities and personnel. The FaCT core will be overseen by a new Core Director who will consolidate the four
facilities administratively, enhance the focus to increase biomedical engineering usage, and manage
personnel, equipment, and facilities. The Core Director will establish the recharge rates for the BEC as it
becomes a recharge center, and oversee annual assessments of recharge rates across the entire facility. To
incentivize CEBs responsive research in the FaCT core, a voucher program will be established to pay recharge
service costs. Finally, the FaCT core will join the ranks of core facilities at BSU, the state of Idaho, and the
Mountain West that are promoted by the INBRE and RAIN programs for use by biomedical researchers in
academia, government, and private industry.
项目总结-制造、表征和测试芯(FACT芯)
FaCT核心将提供RPL和其他人充分参与所需的生物医学工程支持。
开发、合成和验证用于基础或
应用生物医学研究和/或临床转化工作在COBRE的融合工程和
生物分子科学(CEBS)。这一创新的以工程为重点的核心将是现有的四个
工程学院的研究核心,其中三个已经是充电中心。FaCT核心将
合并爱达荷州微加工实验室IML),博伊西州材料表征中心(BSCMC),
工程研究支持中心和生物医学工程中心。满足
根据CEBS COBRE的目标,研究人员必须能够制造各种各样的设备和结构,
简单的机械设备,通过机械加工,印刷或微加工更复杂的传感器。
制造完成后,研究人员还需要能够表征物理,光学和电学特性,
设备/传感器的性能,以评估其性能,用于所需的研究。因此,每项研究
这项工作将需要使用由FaCT核心提供的各种工具、仪器、流程和专业知识
设施和人员。FaCT核心将由一位新的核心总监监督,他将整合四个
行政设施,加强对增加生物医学工程使用的关注,并管理
人员、设备和设施。核心总监将确定BEC的充值费率,
成为充电中心,并监督整个设施的充电率年度评估。到
激励CEB在FaCT核心中的响应性研究,将建立一个代金券计划来支付充值
服务成本。最后,FaCT核心将加入BSU、爱达荷州和
由INBRE和RAIN计划推广,供生物医学研究人员使用,
学术界、政府和私营企业。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Henry Davis其他文献
Paul Henry Davis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 57.29万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 57.29万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 57.29万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 57.29万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 57.29万 - 项目类别:














{{item.name}}会员




